Recent findings from prominent clinical trials, including the ICE3 and FROST trials, indicate that cryoablation presents a highly effective and minimally invasive treatment option for carefully selected patients with early-stage, low-risk breast cancer. The ICE3 trial, with a median follow-up of over 54 months, reported an impressive 5-year ipsilateral breast tumor recurrence (IBTR) rate of just 3.61% among successfully treated patients, with a 5-year local recurrence-free survival rate of 96.39%. Similarly, the FROST trial showed a 5-year IBTR rate of 3.64% overall. A 2025 meta-analysis further supported these findings, noting a pooled local recurrence rate of only 1.1% for patients treated with cryoablation alone. This minimally invasive procedure involves freezing and destroying cancer cells, offering significant advantages over conventional surgery, such as reduced recovery times, less post-procedural pain, minimal scarring, and preserved breast aesthetics. It is particularly suitable for women aged 60 or older with unifocal, ultrasound-visible tumors typically smaller than 1.5 cm, that are hormone receptor-positive, HER2-negative, and node-negative. While generally safe, minor side effects like bruising and swelling can occur. The technology is gaining global acceptance, with its introduction and adoption in India by facilities like Kovai Medical Center and Hospital and Rajiv Gandhi Cancer Institute, making it a relevant and impactful development for the Indian audience facing high breast cancer prevalence. Continued research aims to further optimize its application and explore its potential in combination therapies.